The decree introduces amendments to a previous decision made on June 29, 2018, regarding customs duties on imported goods.

For products classified under position 3004 (according to the Harmonized System of International Trade Classification), the customs duty rate, which was previously set at 0%, will now be set at 2%.

This category includes dosed pharmaceutical products (both mixed and unmixed) intended for therapeutic or prophylactic purposes, packaged either in the form of medicines (including transdermal systems) or for retail sale (excluding products classified under codes 3002, 3005, or 3006).

According to the Harmonized System (HS Code), examples of products under code 3004 include:

- Finished-form antibiotics;
- Painkillers and anti-inflammatory drugs;
- Antiviral medications;
- Hormonal treatments;
- Cardiological drugs;
- Anti-diabetic medications;
- Antihistamines;
- Cancer treatments;
- Vitamins and biologically active supplements classified as medicines.

Products excluded from code 3004 include:

- Ointments, vaccines, and blood products (code 3002);
- Medicinal patches and bandaging materials (code 3005);
- Contrast agents and diagnostic reagents (code 3006).

Code 3004 applies when medicines are cleared through customs for final consumers (as opposed to pharmaceutical substances classified under code 3003).